Objective. To evaluate the effect of rituximab on pathogenic autoantibodies and total Ig levels, and to identify serious adverse events in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with continuous B cell depletion.
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Objective. To evaluate the effect of rituximab on pathogenic autoantibodies and total Ig levels, and to identify serious adverse events in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with continuous B cell depletion.
Methods. We conducted a retrospective analysis of 239 patients with AAV treated with rituximab-induced continuous B cell depletion. Two treatment cohorts were analyzed: an induction group (n 5 52) and a maintenance group (n 5 237). Changes in ANCA titers and total Ig levels over time were evaluated using mixed-effects models. Risk factors for serious infections during maintenance treatment were evaluated using Poisson regression.
Results. During induction, IgG levels fell at a mean rate of 6% per month (95% confidence interval [95% CI] 4, 8%), while ANCA levels declined at a mean rate of 47% per month (95% CI 42, 52%) and 48% per month (95% CI 42, 54%) for patients with antimyeloperoxidase (anti-MPO) antibodies and those with anti-proteinase 3 (anti-PR3) antibodies, respectively. During maintenance treatment, with a median duration of 2.4 years (interquartile range 1.5, 4.0 years), IgG levels declined a mean of 0.6% per year (95% CI 20.2, 1.4%). New significant hypogammaglobulinemia (IgG level of <400 mg/dl) during maintenance treatment occurred in 4.6% of the patients, all of whom were in the lowest baseline IgG quartile. Serious infections during maintenance therapy occurred at a rate of 0.85 per 10 patient-years (95% CI 0.66, 1.1) and were independently associated with an IgG level of <400 mg/dl.
Conclusion. B cell-targeted therapy causes a preferential decline in ANCA titers relative to total IgG levels. Despite prolonged maintenance therapy with rituximab, IgG levels remain essentially constant. Serious infections were rare.
The anti-CD20 monoclonal antibody rituximab has emerged as a useful immunosuppressive agent for the treatment of several antibody-mediated autoimmune diseases (1, 2) . An important immunosuppressive mechanism of rituximab is the attenuation of the production of pathogenic autoantibodies (3) (4) (5) . The potential downside of this therapy is suppression of the protective benefits of the humoral immune system, thus predisposing to infectious complications (6, 7) . The degree to which treatments with rituximab can suppress pathogenic autoantibodies, compared to suppression of protective antibodies, may be a major determinant of the clinical value of these treatments. Characteristics of the disease, variations in the treatment regimen, and patient characteristics may heavily influence this balance.
Rituximab has become an important component of the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) (2, 8, 9) . The Rituximab in ANCA-Associated Vasculitis (RAVE) trial suggested that a regimen with rituximab and glucocorticoids was equivalent to the standard regimen of cyclophosphamide with glucocorticoids for induction of remission (2) . More recently, the Maintenance of Remission using Rituximab in Systemic ANCA-Associated Vasculitis (MAINRITSAN) trial suggested that rituximab with low-dose prednisone is superior to azathioprine with low-dose prednisone as maintenance therapy to prevent disease relapse (9) . An additional randomized controlled trial evaluating rituximab for maintenance of remission is ongoing (10) .
Unfortunately, relapse is common in AAV following cessation of rituximab, and is often heralded by B cell reconstitution (11, 12) . With the aim of preventing disease relapse, our practice has evolved to treat patients for extended periods of time with scheduled rituximab dosing to maintain B cell depletion (13) . Data on the complications of such a treatment regimen, however, are sparse. One particular concern is the development of hypogammaglobulinemia and predisposition to serious infections.
In this study, we retrospectively evaluate the impact of continuous B cell depletion with rituximab on Ig levels during induction and maintenance of remission therapy for AAV. In particular, we compare the relative effect of treatment on the levels of pathogenic auto antibodies versus the effect on total Ig levels. In addition, we describe serious adverse events and identify predictive factors for the development of hypogammaglobulinemia and serious infections.
PATIENTS AND METHODS
Study population and treatment groups. We performed a single-center retrospective analysis of 239 patients with AAV treated with rituximab-induced continuous B cell depletion at the Massachusetts General Hospital Vasculitis and Glomerulonephritis Center from April 2006 to August 2015. Patients were considered to have AAV if they had a positive test result for antibodies to proteinase 3 (PR3) or myeloperoxidase (MPO) together with clinical and laboratory features consistent with granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, or one of the other related forms of vasculitis (14) .
Starting in 2006, our practice evolved into following a consistent treatment regimen for induction and maintenance of remission in the majority of patients. For induction therapy, patients receive combination therapy with rituximab, a 2-month course of low-dose oral cyclophosphamide, and a short course of high-dose steroids with a rapid taper to low dose. The rationale for combining rituximab with cyclophosphamide is to allow for rapid tapering of high-dose glucocorticoids, such that the prednisone dosage is reduced to 15 mg daily by the fifth week of treatment.
For maintenance therapy, patients receive scheduled rituximab treatments with or without low-dose prednisone (#7.5 mg/ day). Prednisone is slowly tapered to discontinuation except as limited by adrenal insufficiency. Rituximab is initially administered as two 1-gm doses intravenously (IV) separated by ;2 weeks. Thereafter, rituximab is administered as a 1-gm dose IV every 4 months for 2 years, followed by a 1-gm dose IV every 6 months. B cell depletion, defined as ,10 CD201 cells/mm 3 , is confirmed using peripheral flow cytometry prior to each rituximab infusion. In the rare event that B cell return is detected, the dosing interval for that patient is shortened.
During induction of remission therapy, all patients receive trimethoprim/sulfamethoxazole as prophylaxis for Pneumocystis jiroveci pneumonia (PCP). Patients with an allergy to sulfonamides are administered atovaquone as an alternative. During maintenance therapy, prophylaxis for PCP is continued until prednisone is completely discontinued and patients are receiving rituximab monotherapy. Patients with a positive hepatitis B core antibody are given either entecavir or lamivudine as prophylaxis for hepatitis B reactivation.
Two treatment groups were analyzed in this study: an induction group and a maintenance group (Figure 1 ). Patients Figure 1 . Composition of the induction and maintenance groups. The induction group comprised 52 patients who received treatment with combination rituximab, cyclophosphamide, and prednisone and had data on baseline and follow-up antineutrophil cytoplasmic antibody (ANCA) titers and IgG levels available. The maintenance group comprised 237 patients in whom remission was achieved after induction therapy or who were transitioned from an alternative maintenance regimen.
were included in the induction group if they had newly diagnosed and active AAV (Birmingham Vasculitis Activity Score for Wegener's Granulomatosis [BVAS/WG] $3) (15), were treated with the induction regimen described above, and had baseline and follow-up IgG and ANCA levels recorded during the induction period. Patients with relapsing disease and patients treated with plasma exchange were excluded. The induction phase began with the first dose of rituximab during induction therapy and ended when complete remission was achieved (defined as a BVAS/WG of 0, a prednisone dosage of #7.5 mg/day, and the absence of immunosuppressants other than rituximab and prednisone).
Patients were included in the maintenance group if they were in complete remission, were being treated with rituximab maintenance therapy as described above, and had baseline and follow-up IgG and ANCA levels recorded during the maintenance period. For patients who had received plasma exchange, inclusion started 180 days after initiation of therapy or after complete remission was attained, whichever was later. Patients who received alternative maintenance regimens were excluded from this analysis. In the event of a disease relapse, patients remained in the maintenance cohort provided they continued to receive scheduled rituximab treatments. Patients who ultimately had rituximab withdrawn were censored at the time of B cell return.
Cases of AAV associated with levamisole were excluded. Likewise, patients with simultaneous membranous nephropathy or anti-glomerular basement membrane disease were excluded. The study was approved by the Partners HealthCare Human Research Committee.
Measurement of Ig and ANCA levels. Ig and ANCA levels were typically measured approximately every 4-6 months in patients receiving continuous B cell depletion as part of clinical care. ANCA titers were measured by enzymelinked immunosorbent assay as previously described (16, 17) .
Briefly, all samples were tested in comparison to a standard reference serum by creation of a standard curve generated from serial 1:2 dilutions. Test samples were diluted 1:16 followed by serial 1:8 dilutions. Concentrations were read off the standard curve and multiplied by the relative dilution to determine the relative concentration. Only dilutions with reactivity falling on the steep part of the reference curve were used for determining the concentration.
For the induction of remission analysis, changes in levels were determined using values from the first measurements closest to the time of initiation of induction treatment (values obtained .2 months before the first dose were excluded) up to 150 days after the first dose of rituximab. In the maintenance of remission analysis, changes in levels were determined using values from the first measurement on or after the date of full remission until the last measurement with documented B cell depletion (,10 B cells/mm 3 ). Serious adverse events and hypogammaglobulinemia. Serious adverse events were defined as events that were life-threatening, led to a hospitalization, caused persistent disability or permanent damage, or resulted in death. Serious adverse events were determined by review of our electronic medical records and flow sheets maintained as part of patient management. Significant hypogammaglobulinemia was defined as an IgG level of ,400 mg/dl. This level was chosen based on prior studies that demonstrated a higher risk of infection below this threshold (18, 19) .
Statistical analysis. All analyses were carried out using Stata version 14. Patient baseline characteristics were stratified by treatment group. Continuous variables are presented as the mean 6 SD or median (interquartile range [IQR]) as appropriate, and categorical variables are presented as percentages. P values for baseline characteristics are not provided because many patients were included in both the induction and maintenance groups, and the observations were not independent.
Mean population changes in Ig levels and ANCA titers were evaluated using linear mixed-effects modeling by regressing log(ANCA titer or Ig level) against time. In the maintenance group, the model was constructed with a random patient-specific intercept and random time effect. Given the limited number of observations per patient in the induction group, models were constructed with a random patient-specific intercept only.
Time to hypogammaglobulinemia during maintenance treatment stratified by baseline IgG level was described using Kaplan-Meier curves. Predictors of hypogammaglobulinemia were evaluated using Cox proportional hazards models. The 95% confidence intervals (95% CIs) and predictors of serious adverse events/infections were evaluated using Poisson regression, treating serious events as a count outcome. For both Cox and Poisson regression, the following covariates were prespecified based on scientific relevance: age, sex, ANCA serotype, baseline IgG level, history of plasma exchange, time from diagnosis of AAV to initiation of rituximab, and duration of continuous B cell depletion prior to remission. Due to the limited number of patients who developed hypogammaglobulinemia, only univariable Cox models were assessed. For Poisson regression, both univariable and multivariable models were constructed. The multivariable model was adjusted for all prespecified covariates listed above.
RESULTS
Baseline characteristics of the patients. Between April 2006 and April 2015, 52 and 237 patients met inclusion criteria for the induction and maintenance groups, respectively. Fifty patients from the induction group were included in the maintenance group. The induction group comprised patients with newly diagnosed and active AAV (BVAS/WG $3) who received a standardized induction regimen. The maintenance group consisted of patients in complete remission (with a BVAS/WG of 0 and a prednisone dosage of #7.5 mg/day) treated with rituximabinduced continuous B cell depletion. Patients in the maintenance group included those treated with a standardized induction regimen in whom complete remission was achieved and those who were already receiving maintenance therapy with an alternative agent and were transitioned to rituximab (Figure 1 ). Patients who transitioned from an alternative maintenance regimen were diagnosed as having AAV a median of 4.3 years (IQR 1.1, 8.1 years) before entering the maintenance cohort. At entry into the maintenance cohort, 92% of the patients were receiving prednisone (median 7.5 mg/day [IQR 5, 7.5]). Thereafter, prednisone was tapered to discontinuation as possible such that by the eighth month of maintenance therapy the median prednisone dosage was 0 mg/day (IQR 0, 4).
Baseline characteristics stratified by treatment group are presented in Table 1 . The median BVAS/WG in the induction group was 6 (IQR 4, 8) and, by definition, was 0 at entry into the maintenance group. The median IgG level at initiation of induction therapy was 797 mg/dl (IQR 643, 1,052) compared with 678 mg/dl (IQR 534, 811) at entry into the maintenance group. Median baseline IgG levels in the maintenance group were lower in patients who received plasma exchange with the standardized induction regimen (559 mg/dl [IQR 445, 642]) compared with those who received the induction regimen alone (665 mg/dl [IQR 554, 792]) or were transitioned from an alternative maintenance regimen (738 mg/dl [IQR 570, 880]) (P , 0.01 for both comparisons).
Among the 50 patients who were included in both groups, the mean within-person decrease in IgG levels from the beginning of induction therapy to the beginning of maintenance therapy was 226 mg/dl (95% CI 155, 298) (P , 0.001). None of the patients in the induction group had significant baseline hypogammaglobulinemia (IgG level of ,400 mg/dl), compared with 9% of the patients in the maintenance group.
Change in Ig levels and ANCA titers with treatment. The population mean change in total Ig levels and ANCA titers during induction therapy is shown in Table 2 and Figure 2 . IgG levels declined at a mean rate of 6% per month (95% CI 4, 8%). ANCA titers showed a more precipitous decline at 47% per month (95% CI 42, 52%) and 48% per month (95% CI 42, 54%) for anti-MPO and anti-PR3 titers, respectively.
Patients in the maintenance therapy group were in a state of continuous B cell depletion for a median of 2.4 years (IQR 1.5, 4.0 years), with the longest duration being 7.6 years. At entry into the maintenance group, 139 patients (59%) continued to have an ANCA titer greater than the cutoff for the assay. The change in ANCA titers in this subset of patients was compared with the change in IgG levels across the entire maintenance group (Table 2 and Figure  2 ). During maintenance therapy with rituximab-induced continuous B cell depletion, IgG levels fell by a mean of 0.6% per year (95% CI 20.2, 1.4%). Conversely, in patients with a positive ANCA titer at the initiation of maintenance treatment, anti-MPO and anti-PR3 titers fell by a mean of 42% per year (95% CI 32, 50%) and 73% per year (95% CI 58, 83%), respectively.
Ig levels and ANCA titers fell more rapidly in induction than in maintenance. When standardized to a common time unit, IgG levels fell 52% per year (95% CI 39, 61%) during induction and 0.6% per year (95% CI 20.2, 1.4%) during maintenance. Likewise, anti-MPO titers decreased by 47% per month (95% CI 42, 52%) during induction compared with 4% per month (95% CI 3, 6%) during maintenance among patients who still had a positive ANCA titer. A similar trend was seen for anti-PR3 titers. In the maintenance group, 13 of 237 patients (5.5%) experienced a major relapse (BVAS/WG .2). All patients were treated with prednisone and continued rituximab, except for 1 patient who also received 2 months of oral cyclophosphamide. A sensitivity analysis demonstrated that continued inclusion of these patients in the maintenance cohort did not influence the results.
Predictors of hypogammaglobulinemia. At entry into the maintenance group, 21 patients (9%) had significant hypogammaglobulinemia (IgG level of ,400 mg/dl). Of the remaining 216 patients with a baseline maintenance IgG level of .400 mg/dl, 10 patients (4.6%) developed significant hypogammaglobulinemia over a median duration of rituximab-induced continuous B cell depletion of 2.4 years (IQR 1.5, 4.0 years). There was no difference in the proportion of patients developing hypogammaglobulinemia among patients treated for disease relapse compared with those who were not (P 5 0.44).
In univariate Cox proportional hazard models, the baseline IgG level at entry into the maintenance group was the only factor associated with subsequently developing significant hypogammaglobulinemia during maintenance therapy with rituximab (HR 0.25 per 50 mg/dl increase in IgG level [95% CI 0.11, 0.56]; P 5 0.001). Duration of continuous B cell depletion prior to entry in the maintenance group was not associated with future significant hypogammaglobulinemia. Likewise, time since the initial diagnosis of AAV, which should serve as a rough surrogate for cumulative non-rituximab immunosuppression, lacked a significant association with developing an IgG level of ,400 mg/dl.
Only patients with a baseline maintenance IgG level in the lowest quartile (408-559 mg/dl) developed significant hypogammaglobulinemia (Figure 3 There were no deaths during induction therapy. However, the induction group inclusion criteria could result in an underreporting of mortality. To address this issue, we analyzed all patients treated with the standardized induction regimen regardless of whether they met criteria for inclusion in the induction group (n 5 89). The majority of the additional 37 patients were not included in the induction group due to the absence of ANCA and IgG levels required for analysis. Among these 89 patients, 2 deaths occurred during the induction period (0.6 deaths per 10 patient-years [95% CI 0.1, 2.4]). One patient died of septic shock in the setting of pneumonia and the other died of a myocardial infarction. During maintenance, there were 0.17 deaths per 10 patient-years (95% CI 0.09, 0.29). Two of the 12 deaths in the maintenance group were attributed to an infectious complication, and none were attributed to a vasculitis flare.
In multivariable models, increasing age and a baseline maintenance IgG level of ,400 mg/dl were associated with developing a serious infection during maintenance therapy with rituximab-induced continuous B cell depletion (Table 3 ). There was no association of serious infection with the duration of AAV prior to rituximab treatment or the duration of rituximab-induced continuous B cell depletion prior to entering the maintenance group. In the 216 patients who entered maintenance with an IgG level of .400 mg/dl, there was no association with IgG level and risk of subsequent serious infections in a univariate and adjusted model (incidence rate ratio 1.02 [95% CI 0.95, 1.09]; P 5 0.65 for the adjusted model).
DISCUSSION
This retrospective analysis of patients with AAV treated with rituximab provides insight into several interesting features of the effect of B cell-targeted therapy on antibody-mediated autoimmune diseases. During induction therapy with combination glucocorticoids, cyclophosphamide, and rituximab, the levels of both pathogenic ANCA and total Ig decline. The decline in ANCA titer, however, occurs at a more rapid rate. There was a 6% (95% CI 4, 8%) per month decline in IgG levels compared with a 47% (95% CI 42, 52%) and 48% (95% CI 42, 54%) per month decline in anti-MPO and anti-PR3 antibodies, respectively. During maintenance therapy with prolonged rituximab-induced continuous B cell depletion, total IgG levels remained essentially constant with a mean decline of 0.6% per year (95% CI 20.2, 1.4%). Furthermore, the rate of serious infections during maintenance therapy was relatively low at 0.85 [95% CI 0.66, 1.1] per 10 patient-years.
A preferential decline in pathogenic ANCA titers allows for a therapeutic window to treat disease while preserving protective humoral immunity. A similar paradigm has been observed in rheumatoid arthritis, whereby treatment with rituximab leads to a sharper decline in rheumatoid factor and antibodies to cyclic citrullinated peptide compared to total Ig levels (3). Given that plasma cells do not express CD20, it is possible that certain diseaseassociated autoantibodies are produced by plasmablasts and plasma cells that are inherently short lived. Alternatively, autoantibody-producing cells may be more sensitive to cyclophosphamide, prednisone, or other induction agents used in conjunction with rituximab. Regardless of which mechanism predominates, the autoantibody-producing plasmablasts and plasma cells are unable to be replenished following B cell depletion. Conversely, disease states in which rituximab fails to induce a preferential decline in disease-associated autoantibodies may be relatively resistant to B cell depletion treatments. For example, treatment of the antiphospholipid syndrome with rituximab has little effect on the levels of autoantibodies and appears to be of limited efficacy in most cases (20) . Given the long-term, relapsing nature of many antibody-mediated autoimmune diseases, the development of hypogammaglobulinemia is a particular concern with repeated courses of rituximab (6, 7) . While prior studies evaluating the effect of B cell-targeted therapy on Ig levels have included heterogeneous populations with varying cumulative rituximab exposure and dosing frequency, our analysis was restricted to patients undergoing continuous B cell depletion. During maintenance treatment, patients receiving scheduled doses of rituximab at 4-6-month intervals showed essentially no change in the mean IgG level despite 25% of patients receiving scheduled rituximab treatments for longer than 4 years. Furthermore, our results suggest that developing hypogammaglobulinemia during maintenance therapy with rituximab is unlikely unless the baseline IgG level is low. Indeed, among patients who entered maintenance therapy in the top 3 IgG quartiles, no patients developed an IgG level of ,400 mg/dl. Therefore, declines in IgG levels are seen primarily during induction therapy, with little change thereafter. We attribute the stability of IgG levels during maintenance to a long-lived plasma cell population that is resistant to immunosuppressive agents and is able to maintain the IgG pool. In agreement with prior reports, the rate of IgM decline we observed was significantly greater than that of IgG (21, 22) . IgA levels fell at a rate similar to that of IgG during induction therapy, but at a rate slightly greater than that of IgG during maintenance therapy.
This stability of IgG levels independent of repeated rituximab doses is consistent with prior reports in the literature. In a large analysis of 2,578 patients with rheumatoid arthritis treated with rituximab in clinical trials (1,043 of whom received $3 rounds of rituximab treatment), 5% of patients developed an IgG level less than the lower limit for the laboratory, and ,1% developed an IgG level of ,300 mg/dl (21) . Importantly, the rate of hypogammaglobulinemia was similar despite the number of rituximab treatments received. In contrast, low IgM levels were observed more commonly, with 23% of patients developing an IgM level below the lower limit of normal for the assay. In another analysis of 243 patients comprised predominantly of patients with AAV, ;16% developed moderate hypogammaglobulinemia (IgG level 300-500 mg/dl) following treatment with rituximab (22) . The pre-rituximab IgG concentration correlated with the development of hypogammaglobulinemia, but the total number of rituximab doses did not. Low IgM levels were significantly more common, with 58% of the patients developing a level of ,30 mg/dl.
The immunosuppressive effects of rituximab extend beyond a potential reduction in total IgG levels. Despite the relative stability of total IgG levels, the ability to manufacture antibodies against new antigens may be impaired. Indeed, patients undergoing treatment with rituximab have an impaired ability to respond to vaccination with pneumococcal polysaccharide or novel antigens (23) . B cell depletion has also been demonstrated to modulate T cell response to infections, which would impair immunity independent of the IgG concentration (24) .
To evaluate the safety of long-term continuous B cell depletion, we reviewed all serious adverse events in our cohort. The rate of serious infections observed in our induction cohort (2.9 per 10 patient-years [95% CI 1.2, 6.0]) is comparable to the rate of grade 3 or 4 infections that occurred in patients receiving induction therapy in the RAVE trial (1.4 per 10 patient-years) (2). In our maintenance cohort, serious infections occurred at a rate of 0.85 per 10 patient-years (95% CI 0.66, 1.1), the vast majority of which were pneumonia. Our results are similar to the rate of grade 3 or 4 infections observed in patients receiving rituximab maintenance therapy in the MAINRITSAN trial (0.82 per 10 patient-years) (9) .
A baseline IgG level of ,400 mg/dl and increasing patient age were associated with an increased risk of serious infections in our maintenance cohort. The association of infectious complications with an IgG level of ,400 mg/dl has been observed in other patient populations. For example, a serum IgG level of ,400 mg/dl was associated with a higher rate of infections compared with more mild reductions in both patients with solid organ transplantation and those with stem cell transplantation (18, 19) . Therefore, particular caution should be exercised in using rituximab in patients with IgG levels approaching this level. Of note, low IgM levels following rituximab treatment were not associated with an increased risk of infections in a prior investigation (21) . Likewise, IgA levels do not appear to be significantly associated with infectious events (25) . The association of prior plasma exchange with a lower risk of serious infections does not have a plausible scientific explanation. Furthermore, other studies evaluating the role of plasma exchange in AAV have not demonstrated this association (26) .
Our study has several strengths and weaknesses. The greatest strengths are the large size for an AAV cohort, long duration of follow-up, and uniformity of treatment. To our knowledge, this cohort provides data on the longest duration of continuous B cell depletion published to date. The main weaknesses are inherent to data collection in retrospective studies. We were only able to accurately record serious adverse events and were not able to provide data on infections that did not require hospitalization. In addition, the exact cumulative dose of cyclophosphamide was unknown for a large percentage of patients transitioned to rituximab from an alternative maintenance regimen, thus precluding a detailed analysis of the effect of cyclophosphamide exposure on IgG levels. Some insight, however, can be derived from the baseline IgG levels of different groups at entry into the maintenance cohort. The 109 patients transitioned to rituximab from an alternative maintenance regimen were diagnosed as having AAV at a median of 4.3 years (IQR 1.1, 8.1 years) before entry into the maintenance cohort and received a minimum of 3-6 months of oral cyclophosphamide for induction of remission. Conversely, those patients who received our standard induction regimen received 2 months of oral cyclophosphamide. There was no difference in baseline maintenance IgG levels or significant hypogammaglobulinemia between these groups, suggesting that cumulative cyclophosphamide exposure alone was not the primary driver of declining IgG levels. Additional investigation is needed to more accurately define the importance of cumulative cyclophosphamide exposure on hypogammaglobulinemia in this setting.
Rituximab has become an important therapy for maintenance of remission in AAV. The results of the MAINRITSAN trial show superior disease control with continuous rituximab compared to maintenance azathioprine. These results await confirmation by the ongoing Rituximab Vasculitis Maintenance (RITAZAREM) trial (10) . In addition, the MAINRITSAN 2 trial is currently underway to compare fixed dosing of rituximab versus dosing contingent upon B cell reconstitution (27) . A previous analysis of our cohort demonstrated that maintenance therapy with rituximab-induced continuous B cell depletion was extremely effective at preventing relapse, with a major disease flare rate of 5% over a median of 2 years (13) .
Since the use of extended courses of rituximab is likely to increase, it is essential to understand the longterm implications of this treatment. This retrospective analysis of 239 patients with AAV undergoing treatment with scheduled doses of rituximab provides several salient insights. While both ANCA and IgG levels decline during induction, pathogenic ANCA levels fall at a more rapid rate. During maintenance therapy, IgG levels remain essentially constant despite prolonged continuous B cell depletion. Serious infections are relatively rare with longterm rituximab therapy and are associated with patient age and significant hypogammaglobulinemia. Further studies are required to help balance the risk of prolonged maintenance therapy against the risk of disease relapse.
